Long-Term Immunosuppression After Solitary Islet Transplantation Is Associated With Preserved XXXX Secretion for More Than a Decade.

@entity1 @entity2690 @entity4053 @entity3446 @entity1723 @entity1140 @entity734 @entity413 @entity479
UNASSIGNED: We report on two @entity1 with @entity1723 ( @entity1723 ) after solitary islet transplantation in 2001. They received @entity479 -sparing immunosuppression (daclizumab, @entity3446 , and @entity1140 according to the Edmonton protocol). Both @entity1 became @entity2690 independent for 2 years: @entity1 A, a 42-year-old female with a 12-year history of @entity1723 , received two islet infusions; @entity1 B, a 53-year-old female with a 40-year @entity1723 history, received one islet infusion. Pretransplant, both had undetectable @entity2690 concentrations and frequent and severe @entity4053 . Pretransplant, hemoglobin A1c (HbA1c) was 7.8% and 8.8% and @entity2690 requirements were 0.47 and 0.33   units/kg/day, respectively. Posttransplant, @entity2690 levels remained detectable while immunosuppression was continued, but decreased over time. @entity2690 was re-started 2 years posttransplant in both @entity1 . Since @entity1 A's glycemia and @entity2690 requirements trended toward pretransplant levels, immunosuppression was discontinued after 13 years. This resulted in a sudden cessation of @entity2690 secretion. @entity1 B continues on immunosuppression, has better HbA1c, and half the @entity2690 requirement compared to pretransplant. Both @entity1 no longer experience severe @entity4053 . Herein, we document blood @entity413 concentrations over time (>30   000 measurements per @entity1 ) and b cell function based on @entity2690 secretion. Despite renewed @entity2690 @entity734 , both @entity1 express satisfaction with having undergone the procedure.
